

# SAÚDE

EM DESTAQUE

V d A E X P E R T I S E



20 a 24 de junho de 2022

---

## LEGISLAÇÃO

---

### NACIONAL

[Resolução da Assembleia Legislativa da Região Autónoma dos Açores n.º 25/2022/A](#)  
**Região Autónoma dos Açores – Assembleia Legislativa**  
Revisão do regime da prestação do trabalho médico extraordinário nos serviços de urgência e de atendimento permanente das unidades de saúde de ilha com serviço de urgência

[Decreto Regulamentar Regional n.º 8/2022/A](#)  
**Região Autónoma dos Açores – Presidência do Governo**  
Procede à primeira alteração do [Decreto Regulamentar Regional n.º 1/2022/A](#), de 21 de janeiro, regime de atribuição de incentivos à fixação, aplicável ao pessoal médico, na Região Autónoma dos Açores

[Decreto Legislativo Regional n.º 13/2022/M](#)  
**Região Autónoma da Madeira – Assembleia Legislativa**  
Regula as atividades de distribuição, venda e aplicação de produtos fitofarmacêuticos para uso profissional e de adjuvantes de produtos fitofarmacêuticos, define os procedimentos de monitorização da utilização dos produtos fitofarmacêuticos para uso profissional e estabelece o regime de inspeção obrigatória dos equipamentos de aplicação de produtos fitofarmacêuticos autorizados para uso profissional na Região Autónoma da Madeira

---

### EUROPEIA

[Regulamento de Execução \(UE\) 2022/944 da Comissão, de 17 de junho de 2022, que estabelece regras de aplicação do Regulamento \(UE\) 2017/746 do Parlamento Europeu e do Conselho no que diz respeito às tarefas dos e aos critérios aplicáveis aos laboratórios de referência da União Europeia no domínio dos dispositivos médicos para diagnóstico in vitro](#)

[Regulamento de Execução \(UE\) 2022/945 da Comissão, de 17 de junho de 2022, que estabelece regras de aplicação do Regulamento \(UE\) 2017/746 do Parlamento Europeu e do Conselho relativas às taxas que podem ser cobradas pelos laboratórios de referência da União Europeia no domínio dos dispositivos médicos para diagnóstico in vitro](#)

---

## REGULAÇÃO

### ECONOMIA E TRANSIÇÃO DIGITAL, FINANÇAS E SAÚDE

[Deliberação n.º 738/2022](#)

Centro Hospitalar Universitário de Lisboa Norte, E. P. E.  
Delegação de competências do conselho de administração

[Deliberação n.º 739/2022](#)

Centro Hospitalar Universitário de Lisboa Norte, E. P. E.  
Distribuição de áreas pelos membros do conselho de administração

[Despacho n.º 7739-A/2022](#)

Negócios Estrangeiros, Defesa Nacional, Administração Interna, Economia e Mar, Saúde e Infraestruturas e Habitação – Gabinetes do Ministro dos Negócios Estrangeiros, da Ministra da Defesa Nacional, dos Ministros da Administração Interna e da Economia e do Mar, da Ministra da Saúde e do Ministro das Infraestruturas e da Habitação

Suspensão das regras aplicáveis à entrada em território nacional, por via aérea, constantes no Despacho n.º 4829-A/2022, de 22 de abril, que integrem as delegações dos diversos países participantes na Segunda Conferência dos Oceanos das Nações Unidas

[Despacho n.º 7739-B/2022](#)

Negócios Estrangeiros, Administração Interna, Saúde e Infraestruturas e Habitação – Gabinetes dos Ministros dos Negócios Estrangeiros e da Administração Interna, da Ministra da Saúde e do Ministro das Infraestruturas e da Habitação

Reconhece a validade do certificado de vacinação da Austrália para efeitos de verificação e aceitação em território nacional e emissão de Certificado Digital COVID da UE

[Despacho n.º 7702/2022](#)

Saúde – Gabinete da Ministra

Designa como chefe do Gabinete da Ministra da Saúde o licenciado Miguel Leal de Faria

[Despacho n.º 7619/2022](#)

Saúde – INFARMED – Autoridade Nacional do Medicamento e Produtos de Saúde, I. P.

Subdelegação de competências do presidente do conselho diretivo, Dr. Rui Santos Ivo, no diretor da Unidade de Projetos Interinstitucionais e para o Sistema de Saúde (USS), Dr. Nuno Filipe Cabrita Vieira Simões

[Publicação para efeitos do artigo 15º-A do Decreto-Lei n.º 176/2006, de 30 de agosto](#) - pedidos de autorização de introdução no mercado de medicamentos genéricos.

[Circulares e Deliberações](#)

[Circular Informativa N.º 067/CD/100.20.200 de 23/06/2022](#) | Lista de medicamentos utilizados por QUE

[Circular Informativa N.º 069/CD/100.20.200 de 24/06/2022](#) | Reporte de consumos de AUE de benefício clínico bem reconhecido

[Notícias](#)

[Boletim de Farmacovigilância, Volume 26, n.º4, abril de 2022](#)

### INFARMED

---

## REGULAÇÃO

---

### DGS

[Informações](#)

[Informação nº 003/2022 de 17/06/2022](#) | Comunicação, medidas preventivas e o envolvimento da comunidade no surto por vírus Monkeypox

[Newsletter](#)

[Newsletter DGS n.º 176 de 2022-06-21](#)

---

### SPMS

[Lista de Entrada em Vigor dos Novos CPA 23-06-2022](#)

---

### HMA

[UPDATE - 'Blue-box' requirements](#)

[UPDATE - National recommendations for requests to act as RMS](#)

[NEW - 21-22 June CMDh Agenda](#)

---

## REGULAÇÃO

Data Processing | Other: [Records of data processing activity relating to the switchboard recording system \(public\) \(updated\)](#)

Medicinal Products for Veterinary Use | [Data requirements for veterinary medicinal products intended to reduce the risk of transmission of vector-borne pathogens in dogs and cats \(updated\)](#)

Medicinal Products for Veterinary Use | Overview of comments: [Overview of comments received on the 'Guideline on data requirements for veterinary medicinal products for the prevention of transmission of vector-borne diseases in dogs and cats' \(EMA/CVMP/EWP/278031/2015\)](#)

Medicinal Products for Veterinary Use | [EudraVigilance Veterinary \(updated\)](#)

Medicinal Products for Veterinary Use | Regulatory and procedural guideline: [Combined Veterinary Dictionary for Drug Regulatory Activities \(VeDDRA\) list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products \(Excel\) \(updated\)](#)

Medicinal Products for Veterinary Use | Regulatory and procedural guideline: [Non-current Veterinary Dictionary for Drug Regulatory Activities \(VeDDRA\) low level terms \(LLT\) and codes \(updated\)](#)

Medicinal Products for Veterinary Use | Other: [Call for comments on the Veterinary Dictionary for Drug Regulatory Activities \(VeDDRA\) standard list for EudraVigilance Veterinary \(EVVet\) \(updated\)](#)

## EMA

Medicinal Products for Veterinary Use | Regulatory and procedural guideline: [Combined Veterinary Dictionary for Drug Regulatory Activities \(VeDDRA\) list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products \(updated\)](#)

Medicinal Products for Veterinary Use | Template or form: [Template for submission of comments for the Veterinary Dictionary for Drug Regulatory Activities \(VeDDRA\) standard list for EudraVigilance Veterinary \(EVVet\) \(updated\)](#)

[Medicinal Products for Veterinary Use](#) | Regulatory and procedural guideline: [List of changes to combined Veterinary Dictionary for Drug Regulatory Activities \(VeDDRA\) list of clinical terms for reporting suspected adverse reactions in animal and humans to veterinary medicinal products \(updated\)](#)

Medicinal Products for Veterinary Use | Regulatory and procedural guideline: [Veterinary Dictionary for Drug Regulatory Activities \(VeDDRA\) dataload friendly file including deprecated terms \(updated\)](#)

Medicinal Products for Veterinary Use | Regulatory and procedural guideline: [Guidance notes on the use of Veterinary Dictionary for Drug Regulatory Activities \(VeDDRA\) terminology for reporting suspected adverse reactions in animals and humans \(updated\)](#)

Medicinal Products for Veterinary Use | [Requirements for the production and control of immunological veterinary medicinal products \(updated\)](#)

Medicinal Products for Veterinary Use | Other: [Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2022 \(updated\)](#)

## REGULAÇÃO

Medicinal Products for Veterinary Use | Regulatory and procedural guideline: [Substances considered as not falling within the scope of Regulation \(EC\) No. 470/2009, with regard to residues of veterinary medicinal products in foodstuffs of animal origin \(updated\)](#)

Events | [Clinical Trials Information System \(CTIS\) bitesize talk: Transitional trials and additional Member State concerned \(MSC\) application, Online, 14:00 - 15:30 Amsterdam time \(CEST\), from 23/06/2022 to 23/06/2022 \(updated\)](#)

Medicinal Products for Human Use | News and press releases: [EMA recommends authorisation of Nuvaxovid for adolescents aged 12 to 17](#)

Medicinal Products for Human Use | Summary of opinion: [COVID-19 Vaccine \(inactivated, adjuvanted\) Valneva, COVID-19 vaccine \(inactivated, adjuvanted, adsorbed\), 23/06/2022, Positive](#)

Medicinal Products for Human Use | Summary of opinion: [Nuvaxovid, COVID-19 Vaccine \(recombinant, adjuvanted\), 23/06/2022, Positive](#)

Medicinal Products for Human Use | News and press releases: [EMA recommends Valneva's COVID-19 vaccine for authorisation in the EU](#)

Corporate | Report: [Annual activity report 2021](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [Procedural guidance for variant strain\(s\) update to vaccines intended for protection against human coronavirus \(updated\)](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [Checklist for annual updates for parallel distribution: guidance for industry \(updated\)](#)

Events | [Extended EudraVigilance medicinal product dictionary \(XEVMPD\) training course for clinical trial sponsors - June 2022, Online, 14:00 - 18:00 Amsterdam time \(CEST\), from 30/06/2022 to 01/07/2022 \(updated\)](#)

Medicinal Products for Veterinary Use | Regulatory and procedural guideline: [Guidance on the details of the classification of variations requiring assessment according to Article 62 of Regulation \(EU\) 2019/6 for veterinary medicinal products and on the documentation to be submitted pursuant to those variations \(updated\)](#)

Events | [European Medicines Agency \(EMA\) Patients' and Consumers' \(PCWP\) and Healthcare Professionals' \(HCPWP\) Working Parties joint meeting, Online, from 01/06/2022 to 02/06/2022 \(updated\)](#)

Medicinal Products for Veterinary Use | Other: [Release notes - production release version 1.6.5 June 2022 - Veterinary Medicinal Products Regulation: Union Product Database](#)

Global Regulators Work | News and press releases: [Global regulators work towards strengthening collaboration on observational research beyond COVID-19 pandemic](#)

Medicinal Products for Human Use | [Type-II variations: questions and answers \(updated\)](#)

Medicinal Products for Human Use | [Pre-authorisation guidance \(updated\)](#)

## EMA

## REGULAÇÃO

### EMA

Medicinal Products for Human Use | Regulatory and procedural guideline: [European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with track changes \(updated\)](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [European Medicines Agency post-authorisation procedural advice for users of the centralised procedure \(updated\)](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure \(updated\)](#)

Medicinal Products for Human Use | Regulatory and procedural guideline: [European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes \(updated\)](#)

Medicinal Products for Human Use | [Renewal and annual re-assessment of marketing authorisation \(updated\)](#)

Medicinal Products for Human Use | [Transfer of marketing authorisation: questions and answers \(updated\)](#)

Medicinal Products for Human Use | [Extensions of marketing authorisations: questions and answers \(updated\)](#)

Events | [Protection of personal data and commercially confidential information \(CCI\) for documents uploaded and published in the Clinical Trials Information System \(CTIS\): Workshop on draft guidance, Online, 10:00-17:00 Amsterdam time \(CEST\), from 14/07/2022 to 14/07/2022](#)

Events | [Union Product Database: webinar on variations not requiring assessment \(VNRAs\) for marketing authorisation holders, Online, 10:00 - 11:30 Amsterdam time \(CEST\), from 08/09/2022 to 08/09/2022](#)

Events | [Committee for Medicinal Products for Human Use \(CHMP\): 20-23 June 2022, European Medicines Agency, Amsterdam, the Netherlands, from 20/06/2022 to 23/06/2022 \(updated\)](#)

Medicinal Products for Human Use | Agenda: [Agenda - CHMP agenda of the 20-23 June 2022 meeting](#)

Events | [Eighth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicine, Online, from 27/06/2022 to 27/06/2022 \(updated\)](#)

Medicinal Products for Human Use | Other: [European Medicines Agency's Data Protection Notice concerning the processing of patient and product traceability data for Zinteglo following the withdrawal of the marketing authorisation](#)

Corporate | [Management Board meeting: 15-16 June 2022, European Medicines Agency, Amsterdam, the Netherlands, from 15/06/2022 to 16/06/2022 \(updated\)](#)

Corporate | News and press releases: [EMA Management Board: highlights of June 2022 meeting](#)

Medicinal Products for Human Use | [Availability of medicines \(updated\)](#)

**EMA**

Clinical Trials Information System | [Clinical Trials Information System: training and support \(updated\)](#)

Events | [Clinical Trials Information System \(CTIS\): Walk-in clinic, Online, 16:00 – 16:45 Amsterdam time \(CEST\), from 15/11/2022 to 15/11/2022 \(updated\)](#)

Events | [Clinical Trials Information System \(CTIS\): Walk-in clinic, Online, 15:00 – 15:45 Amsterdam time \(CEST\), from 12/12/2022 to 12/12/2022 \(updated\)](#)

Events | [Clinical Trials Information System \(CTIS\): Walk-in clinic, Online, 16:00 – 16:45 Amsterdam time \(CEST\), from 20/09/2022 to 20/09/2022 \(updated\)](#)

Events | [Clinical Trials Information System \(CTIS\): Walk-in clinic, Online, 15:00 – 15:45 Amsterdam time \(CEST\), from 05/10/2022 to 05/10/2022 \(updated\)](#)

Events | [Clinical Trials Information System \(CTIS\): Walk-in clinic, Online, 16:00 – 16:45 Amsterdam time \(CEST\), from 22/08/2022 to 22/08/2022 \(updated\)](#)

Medicinal Products for Human Use | News and press releases: [Start of rolling review for adapted Spikevax COVID-19 vaccine](#)

Medicinal Products for Veterinary Use | News and press releases: [Meeting highlights from the Committee for Veterinary Medicinal Products \(CVMP\) 14–15 June 2022](#)

Medicinal Products for Human Use | [Pre-authorisation guidance \(updated\)](#)

**COMISSÃO  
EUROPEIA**

[European Health Union: Political agreement on the Serious Cross-Border Threats to Health Regulation](#)  
[Speech by President von der Leyen at the Vaccine Equity for Africa Ceremony, via video message](#)  
[Webinar recording – Healthier Together – EU Non-communicable diseases initiative \(22 June 2022\)](#)

[SCHEER – Request for a scientific opinion in support of a targeted revision of Annexes III and IV of Directive 2010/63/EU on the protection of animals used for scientific](#)

[EU-Latin America and Caribbean Partnership: manufacturing vaccines, medicines and health technologies and strengthening health systems](#)

[Flash report - Hearing – Managing antimicrobial resistance across the health system](#)

[Video recording – Hearing on Managing antimicrobial resistance across the health system \(20 June 2022\)](#)

[Presentation of the opinion by the Expert Panel – Hearing on Managing antimicrobial resistance across the health system \(20 June 2022\)](#)

[Setting the scene for EU reference labs for high-risk diagnostics](#)

[Summary record – 99th meeting of the Pharmaceutical Committee \(11 May 2022\)](#)

[SCCS – Minutes of the Working Group meeting on Nanomaterials in Cosmetic Products of 9 June 2022](#)



# Contactos



[saude@vda.pt](mailto:saude@vda.pt)

Esta informação é de distribuição reservada, destinando-se exclusivamente aos clientes Vieira de Almeida, e não deve ser entendida como qualquer forma de publicidade, pelo que se encontra vedada a sua cópia ou circulação. A informação proporcionada e as opiniões expressas são de carácter geral, não substituindo o recurso a aconselhamento jurídico adequado para a resolução de casos concretos.